S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:MRVI

Maravai LifeSciences (MRVI) Stock Price, News & Analysis

$8.67
+0.09 (+1.05%)
(As of 03/28/2024 ET)
Today's Range
$8.49
$8.77
50-Day Range
$5.11
$8.76
52-Week Range
$4.52
$16.62
Volume
2.50 million shs
Average Volume
2.59 million shs
Market Capitalization
$2.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.13

Maravai LifeSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
28.3% Upside
$11.13 Price Target
Short Interest
Bearish
6.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
1.25mentions of Maravai LifeSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.15) to ($0.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.81 out of 5 stars

Medical Sector

261st out of 938 stocks

Pharmaceutical Preparations Industry

113th out of 417 stocks

MRVI stock logo

About Maravai LifeSciences Stock (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

MRVI Stock Price History

MRVI Stock News Headlines

Should You Sell Maravai LifeSciences (MRVI)?
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
MRVI Apr 2024 2.500 call
MRVI Apr 2024 2.500 put
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Maravai LifeSciences Shares Rise 65% After 4Q Results
MRVI Jan 2025 5.000 call
MRVI Jan 2025 10.000 put
MRVI Sep 2024 5.000 call
MRVI Jun 2024 15.000 call
Maravai LifeSciences Holdings Inc.
Maravai Lifesciences Holdings Inc (MRVI)
See More Headlines
Receive MRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/29/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRVI
Fax
N/A
Employees
650
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.13
High Stock Price Target
$17.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+28.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-119,030,000.00
Pretax Margin
213.79%

Debt

Sales & Book Value

Annual Sales
$288.95 million
Cash Flow
$0.10 per share
Book Value
$3.14 per share

Miscellaneous

Free Float
250,847,000
Market Cap
$2.18 billion
Optionable
Optionable
Beta
-0.02
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Carl W. Hull (Age 65)
    Co-Founder & Executive Chairman
    Comp: $1.45M
  • Mr. William E. Martin III (Age 48)
    Chief Executive Officer
    Comp: $2.07M
  • Mr. Kevin M. Herde (Age 52)
    Executive VP & CFO
    Comp: $778.28k
  • Dr. Peter Michael Leddy Ph.D. (Age 61)
    Executive VP & Chief Administrative Officer
    Comp: $757k
  • Ms. Christine Dolan (Age 56)
    Executive Vice President of Biologics Safety Testing
    Comp: $755.97k
  • Ms. Debra Hart
    Senior Director of Investor Relations
  • Mr. Kurt Oreshack (Age 43)
    Executive VP, General Counsel & Secretary
    Comp: $701.4k
  • Ms. Becky Buzzeo
    Executive VP & Chief Commercial Officer
  • Dr. Kate E. Broderick Ph.D.
    Chief Innovation Officer
  • Mr. Christopher Benoit
    Executive Vice President of Enzymes

MRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Maravai LifeSciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MRVI shares.
View MRVI analyst ratings
or view top-rated stocks.

What is Maravai LifeSciences' stock price target for 2024?

9 Wall Street research analysts have issued twelve-month target prices for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $17.00. On average, they anticipate the company's stock price to reach $11.13 in the next year. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for MRVI
or view top-rated stocks among Wall Street analysts.

How have MRVI shares performed in 2024?

Maravai LifeSciences' stock was trading at $6.55 on January 1st, 2024. Since then, MRVI stock has increased by 32.4% and is now trading at $8.67.
View the best growth stocks for 2024 here
.

When is Maravai LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our MRVI earnings forecast
.

How were Maravai LifeSciences' earnings last quarter?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The company earned $74.14 million during the quarter, compared to the consensus estimate of $62.99 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 1.31% and a negative net margin of 41.19%.

What ETFs hold Maravai LifeSciences' stock?
What guidance has Maravai LifeSciences issued on next quarter's earnings?

Maravai LifeSciences updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $265.0 million-$285.0 million, compared to the consensus revenue estimate of $261.0 million.

When did Maravai LifeSciences IPO?

Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers.

Who are Maravai LifeSciences' major shareholders?

Maravai LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.98%), Vanguard Group Inc. (3.98%), Massachusetts Financial Services Co. MA (2.39%), Mackenzie Financial Corp (2.06%), Braidwell LP (2.01%) and Pacer Advisors Inc. (1.18%).

How do I buy shares of Maravai LifeSciences?

Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRVI) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners